SEC Form 4 · accession 0001193125-26-308041
KESTRA MEDICAL TECHNOLOGIES, LTD. · KMTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Daniel Webster
Officer — See Remarks · Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 5:48 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001877184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jul 15, 2026 | A | 176,470 | $0.00 | A | 571,937 | D | |
| Common SharesF3 | Jul 15, 2026 | S | 11,216 | $22.0105 | D | 560,721 | D | |
| Common SharesF4 | Jul 15, 2026 | S | 784 | $22.6333 | D | 559,937 | D | |
| Common SharesF5 | Jul 15, 2026 | S | 3,000 | $23.9983 | D | 556,937 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.
- F2The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
- F3The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F4The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- F5The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Remarks
President and Chief Executive Officer